Benitec Biopharma Inc. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

Benitec Biopharma's Business Model

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

About Benitec Biopharma

Website: https://benitec.com

CEO (Chief Executive Officer): Dr. Jerel A. Banks M.D., Ph.D.

IPO date: 2014-06-24

Contact

Country: US

Address: 3940 Trust Way

City: Hayward

State: CA

Phone: 510 780 0819

Zip Code: 94545

Other

CIK: 0001808898

ISIN: US08205P2092

CUSIP: 08205P100

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.